The trial is being carried out at the University of Arizona Cancer Center with Hani Babiker, M.D., as Principal Investigator.
There are approximately 47,000 new cases of metastatic melanoma in the US each year, with approximately 10,000 deaths.
More than 15,000 of these patients develop brain metastases. The median overall survival for patients with brain metastases is 4 months. Approximately 50% of patients harbor BRAF- or MEK-mutated melanoma, with limited treatment options are available.
Targeted therapies and immune checkpoint inhibitors have improved overall survival for metastatic melanoma patients with brain metastases. However, responses are usually of short duration and new agents that effectively penetrate the blood brain barrier are needed.
E6201 is an ATP-competitive MEK1 inhibitor that has demonstrated preclinical activity in BRAF V600E mutant melanoma cell lines. E6201 has shown excellent brain distribution characteristics and minimal CNS efflux by transporters at the blood brain barrier.
A Phase 1 trial (NCT00794781) evaluating E6201 in 55 patients with advanced solid tumors demonstrated activity in metastatic melanoma patients, including two patients with brain metastases, one of whom maintains an exceptional ongoing durable response lasting for almost 9 years.
The University of Arizona Cancer Center is one of only 45 National Cancer Institute designated Comprehensive Cancer Centers in the nation.
That designation is reserved for centers focusing on patient care as well as basic and clinical research, prevention, education, outreach and training. The Cancer Center is in research on women's cancers (breast, ovarian), men's cancers (prostate), gastrointestinal cancers (colon, pancreas and liver), lymphoma and skin cancers and is home to one of the largest Cancer Prevention and Control Programs.
Spirita Oncology is an integrated oncology research and development company with experience in developing, managing and optimising global pharmaceutical drug development programs from late discovery, translational research and clinical development through market authorization and post-marketing life-cycle management.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference